Robert Mashal, Director at Nuvation Bio Inc. (NUVB), bought 25,000 shares at $4.73 ($118K) on 2026-06-09, disclosed to the SEC on 2026-06-11.
Director Robert Mashal purchased $118,250 worth of Nuvation Bio shares at $4.73, marking the largest insider purchase in the company's history. This significant buy signals confidence in the stock's potential recovery following a recent pullback.
The stock is down 7.0% over the last five days and is currently trading 50.97% below its 52-week high of $9.75, despite a 117.27% one-year gain.
1) Q2 2026 earnings on August 6, 2026, where the company beat revenue estimates by 16.86%. 2) Upcoming detailed subgroup efficacy and safety readouts for IBTROZI presented on August 4, 2026. 3) A Zacks article on July 30, 2026, highlighting the stock's potential to beat earnings estimates.
The stock has a high short interest of 25.21% of the float, and recent news on July 21, 2026, noted that earnings estimate revisions might not support further near-term upside.
Something here stands out, but not much.
| Filing → |